NeuroKaire Overview
NeuroKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The NeuroKaire test predicts the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Israeli startup NeuroKaire launches world’s first blood test to personalize depression treatment | CTech
NeuroKaire, formerly known as Genetika+, has launched BrightKaire, a groundbreaking test that uses AI and stem-cell technology to personalize antidepressant treatment for patients with major depressive disorder (MDD). This innovation, which has received regulatory approval in the U.S., allows for a more accurate and faster determination of effective medication, potentially reducing the trial-and-error period from years to weeks. The company has raised $25 million from venture capital funds and secured additional grants from the European Union. BrightKaire is available in the U.S. and Israel, with tests conducted in the U.S. NeuroKaires approach represents a significant advancement in personalized psychiatry, offering hope for more effective treatment of depression.
Product StageInvestmentCustomersPartners
growth-positive
/PRNewswire/ -- NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, has successfully secured $10...
NeuroKaire, a biotechnology company specializing in precision medicine for psychiatry and neurology, has secured $10 million in funding to advance its clinical test for identifying drug efficacy in depression patients. The funding round was led by GreyBird Ventures, with participation from Meron Capital and Jumpspeed Ventures. This investment will enable NeuroKaire to scale operations, expand its team, and deepen research and development efforts. The company aims to enhance its pharmaceutical partnerships and drive innovation in drug discovery and development. NeuroKaires innovative test provides insights into brain function and drug response, helping clinicians identify the optimal antidepressant for patients. The company is poised to transform treatment paradigms in depression and improve the efficiency of new drug development.
InvestmentPartnersExpand
growth-positive
Clexio and Genetika+ announce partnership using proprietary antidepressant screening platform
Clexio and Genetika+ are partnering to screen and characterize Clexios antidepressant pipeline using Genetika+s iPSC-derived neurons platform. This partnership allows for the assessment of the functional effects of drugs directly on human neurons, enabling a readout of the antidepressant effect of a candidate drug and the characterization of a compound with respect to its effect on different depression subpopulations. The collaboration aims to contribute to the advancement of personalized medicine for psychiatry. Clexio is a CNS-first clinical stage pharmaceutical company dedicated to developing novel therapies for neurological and psychiatric conditions. Genetika+ is developing personalized medicine solutions for psychiatric and neurological diseases.
Partners
growth-positive
Genetika+ obtains CE-IVD mark for NeuroKaire blood test
Genetika+ has obtained a CE-IVD mark for its new blood test, NeuroKaire, which aims to optimize treatment for depression. The AI-powered tool helps physicians determine the optimal antidepressant treatment required for major depressive disorder (MDD) patients. The test has been developed using data collected from MDD patients and leverages advanced AI and machine learning approaches. A multi-site study showed high accuracy in predicting drug response in MDD patients, validating NeuroKaires efficacy. Genetika+ plans to collaborate with hospitals and physicians to launch the tool in regular clinical practice. The CE-IVD mark demonstrates the accuracy and efficacy of NeuroKaire and facilitates its adoption in the European market. MDD is estimated to affect over 300 million people globally.
Customers
growth-positive
Genetika+ Announces CE Mark for NeuroKaire™ its AI-powered Tool to Optimize Depression Treatment
Genetika+ has announced the CE-IVD mark for NeuroKaire, a blood test that predicts drug response in patients with major depressive disorder (MDD). The test is designed to assist physicians in prescribing the optimal antidepressant treatment for MDD patients. Genetika+ is partnering with physicians and hospitals to implement the tool in routine clinical practice. The NeuroKaire test combines AI-driven biomarkers, pharmacogenetics, and clinical data to provide accurate predictions of drug response. The CE mark follows successful results from a multi-site study, validating the efficacy of NeuroKaire. MDD affects over 300 million people globally, and there is a significant unmet need for a product like NeuroKaire to improve treatment outcomes and reduce healthcare costs associated with suboptimal disease management.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $25.27M |
| Last funding | $10M |
| Stage | A |
| Rounds | 7 |
| Investors | 7 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.neurokaire.com |
| Careers | Careers page |
Locations
Yigal Alon St 126, Tel Aviv-Yafo, Israel
78 John Miller Way, Kearny, NJ 07032, USA
Photos & Videos
1 item(s)
